Company / Revenue
Corcept Therapeutics Incorporated Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$761.4M
FY2025
5-year range
$306.5M / $761.4M
FY2021-FY2025
Trend
+12.8%
vs FY2024
Sector context
#49 of 155
Health Care
What the data says
At $761M, Corcept Therapeutics Incorporated's revenue ranks #49 of 155 in the Health Care sector. Revenue has increased for 7 consecutive years, from $81M in FY2018 to $761M in FY2025.
Based on SEC 10-K filings.
$761M in FY2025 with a 5-year CAGR of +24.8%.
Improved from $482M to $761M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +29.1%
- 5-Year CAGR
- +24.8%
- 10-Year CAGR
- -
Sector benchmark
#49 of 155 in Health CareTop 32% of 155This company $761.4M Sector average $4.5B
▼
-83.0% below sector average
Key checks
Key Insights
- Corcept Therapeutics Incorporated's revenue has grown for 7 consecutive years.
- 5-year CAGR of +24.8%, indicating consistent growth.
- In FY2025, revenue increased 12.8% year-over-year.
- Ranks #49 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.44 (safe zone, above 2.9 threshold)
- Strong profit margin: 20.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $761.4M | +12.8% |
| FY2024 | $675.0M | +39.9% |
| FY2023 | $482.4M | +36.3% |
| FY2022 | $353.9M | +15.5% |
| FY2021 | $306.5M | +22.0% |
| FY2020 | $251.2M | +57.8% |
| FY2019 | $159.2M | +95.8% |
| FY2018 | $81.3M | -48.9% |
| FY2017 | $159.2M | +499.6% |
| FY2016 | $26.6M | -47.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026